Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.47 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.47 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3839930 | 1.00 | GPR84 (0.48) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5331990 | 0.98 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5599848 | 0.98 | GPR84 (0.52) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL10010696 | 0.85 | CHRM1 (0.46) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL1713102 | 0.81 | FFAR4 (0.46) | GPR84FFAR1PPARDFFAR4 | |
| SCHEMBL10011524 | 0.81 | SLC1A2 (0.37) | SLC1A2 | |
| SCHEMBL1712183 | 0.80 | FOLH1 (0.39) | GPR84FFAR1PPARDFFAR4 | |
| SCHEMBL10010150 | 0.79 | SLC1A2 (0.36) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6539103 | 0.79 | MAPT (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL10012340 | 0.78 | SLC1A2 (0.38) | SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1845901-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-11 | — | — | CN | claimed |
| CN-100522947-C | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-05 | — | — | CN | disclosed |
| CN-101023062-A | Production of alpha, beta-unsaturated esters and acids by stereoselective dehydration | JANSSEN PHARMACEUTICA NV (BE) | 2007-08-22 | — | — | CN | disclosed |
| CN-1845901-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2006-10-11 | — | — | CN | disclosed |
| CN-1678587-A | CCK-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2005-10-05 | — | — | CN | disclosed |
| US-RE37670-E1 | Antiproliferative and neurotrophic molecules | AMERICAN BIOGENETICS INC. | 2002-04-23 | — | — | US | disclosed |
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | NAU HEINZ (DE) | 2002-01-31 | — | — | US | disclosed |
| US-6300373-B1 | CONTACTING NEURONAL CELLS WITH A NEUROTROPHIC AMOUNT CARBOXYLIC ACID DERIVATIVE FOR PROVIDING NEUROTROPHIC ACTIVITY | AMERICAN BIOGENETIC SCIENCES, INC. | 2001-10-09 | — | — | US | disclosed |
| US-6274624-B1 | COMPOUNDS SUCH AS 2-N-PENTYL-4-PENTYNOIC ACID AS ANTIMITOTIC AGENTS | AMERICAN BIOGENETIC SCIENCES INC. | 2001-08-14 | — | — | US | disclosed |
| EP-0778820-B1 | NEUROTROPHIC AND ANTIPROLIFERATIVE COMPOUNDS | AMERICAN BIOGENETIC SCIENCES (US) | 2001-05-02 | — | — | EP | disclosed |
| US-5672746-A | UNSATURATED ALKYL CARBOXYLIC ACIDS(AND THEIR SALTS) FOR TREATMENT OR PREVENTION OF NERVOUS SYSTEM DISORDERS | AMERICAN BIOGENETIC SCIENCES, INC. (US) | 1997-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013367-A1 | Antiproliferative and neurotrophic molecules | BDNF, NGF, NTRK2 | GPR84 2604/4885FFAR1 1051/4885MAPT 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.